

# Ferroptosis-Related *APOE*, *BCL3* and *ALOX5AP* Gene Polymorphisms are Associated with the Risk of Thyroid Cancer

Zhifu Xiao<sup>1,\*</sup>, Haixia Zhao<sup>2,\*</sup>

<sup>1</sup>Department of Thyroid Surgery, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, 030012, People's Republic of China; <sup>2</sup>Central Lab, General Hospital of Taiyuan Iron and Steel Group, Taiyuan, Shanxi, 030003, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Zhifu Xiao, Department of Thyroid Surgery, Shanxi Provincial People's Hospital, 29 Shuangtasi Road, Taiyuan, Shanxi, 030012, People's Republic of China, Tel/Fax +86 0351-4960327, Email wangxiaozhifu@126.com

**Purpose:** This study aimed to evaluate the association between polymorphisms in the ferroptosis-related genes apolipoprotein E (*APOE*), *BCL3* transcription coactivator (*BCL3*) and arachidonate 5-lipoxygenase activating protein (*ALOX5AP*) and the risk of thyroid cancer.

**Methods:** Six single nucleotide polymorphisms (SNPs) of *APOE* (rs429358 and rs7412), *BCL3* (rs34698726 and rs8100239) and *ALOX5AP* (rs4076128 and rs4073259) were genotyped in 520 papillary thyroid carcinoma cases and 520 healthy controls using the MassARRAY platform.

**Results:** The rs429358-TC, rs34698726-TA/TT, and rs8100239-AT/AA genotypes exhibited an elevated risk of thyroid cancer ( $p_{rs429358} = 0.002$ ,  $p_{rs34698726} = 0.007$ ,  $p_{rs8100239} = 0.002$ ), while rs7412-CT/TT and rs4076128-GA/GG were found to be protective genotypes against the risk of disease ( $p_{rs7412} = 0.0003$ ,  $p_{rs4076128} = 0.0001$ ). Genetic model analysis showed that *APOE*-rs429358 was correlated with an increased risk of disease under dominant and log-additive models ( $p_{dominant} = 0.0004$ ,  $p_{log-additive} = 0.0006$ ). *BCL3*-rs34698726 and rs8100239 were associated with an elevated risk of disease under all three genetic models ( $p < 0.05$ ). In contrast, *APOE*-rs7412 was related to a decreased risk of thyroid cancer under dominant and log-additive models ( $p_{dominant} = 0.0001$ ,  $p_{log-additive} = 0.0001$ ). Moreover, *ALOX5AP*-rs4076128 was also correlated with a reduced risk of disease under all three genetic models ( $p < 0.05$ ).

**Conclusion:** The results help us better understand how genetic polymorphisms in ferroptosis-related genes are relevant to thyroid cancer susceptibility.

**Keywords:** thyroid cancer, single nucleotide polymorphisms, SNPs, *APOE*, *BCL3*, *ALOX5AP*

## Introduction

Thyroid cancer is the most common endocrine system malignant tumor, ranking as the ninth most commonly diagnosed cancer in the world.<sup>1</sup> The incidence of the disease is related to region, race, and sex, and the incidence in women is two to four times higher than that in men.<sup>2</sup> There are four pathological types: papillary carcinoma, follicular carcinoma, undifferentiated carcinoma and medullary carcinoma.<sup>3</sup> Papillary carcinoma is the most common type of thyroid cancer, with low malignancy and good prognosis.<sup>4</sup> Ionizing radiation has been identified as a direct risk factor for thyroid cancer,<sup>5</sup> and obesity, smoking, hormonal exposure and environmental pollutants have also been considered risk factors for the disease.<sup>6</sup> Genetic factors have important functions in the onset of thyroid cancer, and previous studies have reported many variants associated with the disease.<sup>7-9</sup> However, to date, the etiology of thyroid cancer is still not well elucidated, and novel targets for the early diagnosis and treatment of the disease are urgently needed.

Ferroptosis refers to programmed cell death characterized by iron ion-dependent lipid reactive oxygen production and peroxidative damage of cell membrane lipids.<sup>10</sup> In recent years, an increasing number of studies have revealed that ferroptosis is closely associated with the onset and development of cancer and have brought new possibilities for cancer therapeutics.<sup>11</sup> A recent study identified several ferroptosis-related genes that may influence the immune infiltration and progression of thyroid cancer, including apolipoprotein E (*APOE*), BCL3 transcription coactivator (*BCL3*), and arachidonate 5-lipoxygenase activating protein (*ALOX5AP*).<sup>12</sup> *APOE* is an important apoprotein that binds to peripheral cell receptors and is essential for the catabolism of triglyceride-rich lipoprotein constituents. Abnormal expression of *APOE* has been involved in the tumorigenesis of several cancers, such as melanoma and breast and colorectal cancer.<sup>13–15</sup> *BCL3* is a proto-oncogene that functions as a transcriptional coactivator that is activated through its association with NF-kappa B homodimers.<sup>16</sup> *BCL3* is deregulated in many cancers, including breast, colorectal, and prostate cancers.<sup>17–19</sup> *ALOX5AP* localizes to the plasma membrane and is involved in the transport and activation of 5-lipoxygenase. *ALOX5AP* has been widely investigated in various types of inflammatory responses and cancers.<sup>20</sup> However, little information is available about the single nucleotide polymorphisms (SNPs) of *APOE*, *BCL3* and *ALOX5AP* in thyroid cancer.

In this study, we selected six SNPs in *APOE*, *BCL3* and *ALOX5AP* based on previous association studies. *APOE*-rs429358 has been associated with breast cancer, myocardial infarction and gallbladder disease.<sup>21,22</sup> *APOE*-rs7412 is correlated with the risk of T2DM in Egyptians.<sup>23</sup> Rs34698726 and rs8100239 in *BCL3* are associated with the risk of breast cancer and survival of lung cancer, respectively.<sup>24,25</sup> *ALOX5AP*-rs4076128 interacts with dietary linoleic acid intake in breast cancer patients,<sup>20</sup> and *ALOX5AP*-rs4073259 has been detected in patients with ischemic stroke and cerebral infarction.<sup>26,27</sup> Given the evidence above, we speculated that these SNPs may also be involved in the onset and progression of thyroid cancer. Therefore, we genotyped these SNPs in our thyroid cancer case–control cohort and evaluated the association between the SNPs and the risk of disease.

## Materials and Methods

### Subjects

In total, 520 thyroid cancer cases and 520 healthy controls were collected at Shanxi Provincial People's Hospital. The diagnosis of thyroid cancer was established by histopathological examination of biopsy or resected tissue specimens. All cases were newly diagnosed papillary thyroid carcinoma and previously untreated. The controls were blood donors without a history of cancer, immune disorder or serious disease. All participants provided written informed consent. This study was approved by the Ethics Committee of Shanxi Provincial People's Hospital and carried out in accordance with the World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.

### Genotyping

Five milliliters of whole blood was collected from each subject in tubes containing ethylenediaminetetraacetic acid. DNA was extracted using a PureLink™ Pro 96 Genomic DNA Purification Kit (Invitrogen, Carlsbad, CA). Primers were designed using Sequenom MassARRAY Assay Design 3.0 software, and genotypes were detected by Sequenom MassARRAY RS1000 (Sequenom, San Diego, CA).

### Statistical Analyses

Statistical analyses were performed with SPSS package version 20.0 (SPSS, Chicago, IL, USA). Minor allele frequencies (MAFs) in controls were checked for departure from Hardy–Weinberg equilibrium (HWE) in controls. HaploReg v4.1 (<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>) was used to predict the potential functions of the SNPs. The associations between SNPs and thyroid cancer risk were evaluated using SNPstats (<https://www.snpstats.net/start.htm>) and are expressed as the odds ratios (ORs) and 95% confidence intervals (CIs). Statistical significance was established when  $p < 0.05$ .

**Table 1** The Basic Information of the Participants

Characteristics	Case (n=520)	Control (n=520)	$\chi^2/t$	<i>p</i>
Sex (%)				
Male	166 (31.9)	174 (33.5)	0.280	0.597
Female	354 (68.1)	346 (66.5)		
Age				
Mean±SD	49.99±12.54	49.22±12.12	0.382	0.313

## Results

The basic information of the participants is described in Table 1. The cases included 166 males and 354 females, with a mean age of 49.9 years, and the control group contained 174 males and 346 females, with a mean age of 49.22 years. No significant differences were observed in the distribution of sex or age between the two groups ( $p > 0.05$ ).

The basic information and predicted functions of candidate SNPs are listed in Table 2. The predicted function according to the HaploReg database showed that rs429358 and rs7412 in *APOE* were missense variants and led to changed amino acids. In addition, rs34698726 and rs8100239 in *BCL3* and rs4076128 and rs4073259 in *ALOX5AP* were involved in the regulation of the promoter or enhancer histone, DNase, changed motifs, and eQTL hits.

The MAFs of SNPs in thyroid cancer cases and healthy controls are presented in Table 3. All of the SNPs were consistent with HWE ( $p > 0.05$ ). Comparing the MAFs of each SNP between cases and controls, we found that five SNPs had potential effects on thyroid cancer risk: rs429358 and rs7412 in *APOE*, rs34698726 and rs8100239 in *BCL3*, and rs4076128 in *ALOX5AP*. The minor alleles of rs429358, rs34698726 and rs8100239 were associated with an increased risk of thyroid cancer (rs429358: OR = 1.465, 95% CI: 1.170–1.833,  $p = 0.001$ ; rs34698726: OR = 1.316, 95% CI: 1.103–1.569,  $p = 0.002$ ; rs8100239: OR = 1.410, 95% CI: 1.163–1.709,  $p < 0.001$ ). In contrast, the minor alleles of rs7412 and rs4076128 were correlated with a decreased risk of disease (rs7412: OR = 0.585, 95% CI: 0.446–0.767,  $p < 0.001$ ; rs4076128: OR = 0.698, 95% CI: 0.584–0.835,  $p < 0.001$ ).

The genotype frequencies of SNPs in cases and controls are shown in Table 4. Compared with the TT genotype of rs429358, the TC genotype exhibited a 1.59-fold increased risk of thyroid cancer ( $p = 0.002$ ). The TA and TT genotypes of rs34698726 were related to a 1.33-fold and 1.79-fold elevated risk of disease, respectively ( $p = 0.007$ ). Moreover, the AT and AA genotypes of rs8100239 were associated with a 1.32-fold and 2.09-fold increased risk of disease, respectively ( $p = 0.002$ ). In contrast, the CT and TT genotypes of rs7412 were found to be protective against the risk of thyroid cancer

**Table 2** Basic Information and Predicted Functions of Candidate SNPs

SNP	Gene	Position	Allele	Role	Predicted Functions
rs429358	<i>APOE</i>	chr19:44908684	T>C	Missense Variant	Cys130Arg
rs7412	<i>APOE</i>	chr19:44908822	C>T	Missense Variant	Arg176Cys
rs34698726	<i>BCL3</i>	chr19:44740744	A>T	Upstream Variant	Enhancer histone mark, motifs changed, eQTL hits
rs8100239	<i>BCL3</i>	chr19:44749847	T>A	Intron Variant	DNase, motifs changed
rs4076128	<i>ALOX5AP</i>	chr13:30731006	A>G	Intron Variant	Promoter/Enhancer histone marks, DNase, motifs changed, eQTL hits
rs4073259	<i>ALOX5AP</i>	chr13:30732134	A>G	Intron Variant	Promoter/Enhancer histone marks, DNase, motifs changed, eQTL hits

**Abbreviations:** SNP, single nucleotide polymorphism; eQTL, expression quantitative trait locus.

**Table 3** The MAF and HWE of Candidate SNPs in Thyroid Cancer Cases and Healthy Controls

SNP	Gene	MAF-Cases	MAF-Controls	HWE <i>p</i>	OR (95% CI)	<i>p</i>
rs429358	APOE	0.21	0.15	0.99	1.465 (1.170–1.833)	0.001*
rs7412	APOE	0.09	0.15	0.73	0.585 (0.446–0.767)	<0.001*
rs34698726	BCL3	0.43	0.36	0.51	1.316 (1.103–1.569)	0.002*
rs8100239	BCL3	0.32	0.25	0.64	1.410 (1.163–1.709)	<0.001*
rs4076128	ALOX5AP	0.33	0.41	0.21	0.698 (0.584–0.835)	<0.001*
rs4073259	ALOX5AP	0.45	0.43	0.18	1.076 (0.906–1.280)	0.402

Note: \**p* < 0.05 indicates statistical significance.

Abbreviations: SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium.

(*p* = 0.0003), and the GA and GG genotypes of rs4076128 were also associated with a decreased risk of disease (*p* = 0.0001).

The influence of SNPs on the risk of thyroid cancer was further evaluated using three genetic models (Table 5). *APOE*-rs429358 was correlated with an increased risk of disease under dominant and log-additive models (*p*<sub>dominant</sub> = 0.0004, *p*<sub>log-additive</sub> = 0.0006). *BCL3*-rs34698726 and rs8100239 were associated with an elevated risk of disease under all

**Table 4** Genotype Frequency Distributions Between Thyroid Cancer Cases and Healthy Controls

SNP	Gene	Genotype	Control	Case	OR (95% CI)	<i>p</i>
rs429358	APOE	TT	371 (71.3%)	317 (61%)	1	0.002*
		TC	137 (26.4%)	186 (35.8%)	1.59 (1.22–2.08)	
		CC	12 (2.3%)	17 (3.3%)	1.68 (0.79–3.57)	
rs7412	APOE	CC	376 (72.3%)	427 (82.1%)	1	0.0003*
		CT	134 (25.8%)	90 (17.3%)	0.59 (0.43–0.79)	
		TT	10 (1.9%)	3 (0.6%)	0.26 (0.07–0.95)	
rs34698726	BCL3	AA	208 (40%)	166 (31.9%)	1	0.007*
		TA	248 (47.7%)	264 (50.8%)	1.33 (1.02–1.74)	
		TT	64 (12.3%)	90 (17.3%)	1.79 (1.22–2.62)	
rs8100239	BCL3	TT	297 (57.1%)	251 (48.3%)	1	0.002*
		AT	189 (36.4%)	209 (40.2%)	1.32 (1.02–1.71)	
		AA	34 (6.5%)	60 (11.5%)	2.09 (1.33–3.28)	
rs4076128	ALOX5AP	AA	171 (32.9%)	236 (45.4%)	1	0.0001*
		GA	267 (51.4%)	224 (43.1%)	0.61 (0.47–0.79)	
		GG	82 (15.8%)	60 (11.5%)	0.53 (0.36–0.78)	
rs4073259	ALOX5AP	AA	175 (33.6%)	158 (30.4%)	1	0.470
		GA	240 (46.1%)	255 (49%)	1.19 (0.90–1.57)	
		GG	105 (20.2%)	107 (20.6%)	1.13 (0.80–1.60)	

Note: \**p* < 0.05 indicates statistical significance.

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

three genetic models ( $p < 0.05$ ). In contrast, *APOE*-rs7412 was related to a decreased risk of thyroid cancer under dominant and log-additive models ( $p_{\text{dominant}} = 0.0001$ ,  $p_{\text{log-additive}} = 0.0001$ ). Moreover, *ALOX5AP*-rs4076128 was also correlated with a reduced risk of disease under all three genetic models ( $p < 0.05$ ).

The morbidity of thyroid cancer in females was higher than that in males. Therefore, stratified analysis was carried out according to sex (Table 6). *BCL3*-s34698726 was correlated with an elevated risk of thyroid cancer in both males and females ( $p < 0.05$ ). Moreover, *APOE*-rs7412 and *ALOX5AP*-rs4076128 were associated with a decreased risk of disease in both males and females ( $p < 0.05$ ). However, *APOE*-rs429358 and *BCL3*-rs8100239 were associated with an increased risk of disease only in females. In addition, *ALOX5AP*-rs4073259 was found to be associated with an increased risk of disease ( $p = 0.006$ ).

## Discussion

With in-depth study, ferroptosis has gradually exhibited enormous potential in cancer prevention and treatment. However, few studies have focused on ferroptosis-related gene polymorphisms in thyroid cancer. In this study, we genotyped six SNPs in the ferroptosis-related genes *APOE*, *BCL3* and *ALOX5AP* and found that rs429358, rs34698726 and rs8100239 were associated with an increased risk of thyroid cancer. In contrast, rs7412 and rs4076128 were related to a decreased risk of disease.

*APOE* is a polymorphic protein and has multiple functions in the transport and catabolism of triglycerides and cholesterol. It can bind to the receptors of low-density lipoprotein and chylomicron and therefore regulate lipid metabolism.<sup>28</sup> Based on its function, the abnormal expression and dysregulation of *APOE* has been widely investigated in earlier studies about the etiology and pathogenesis of diseases related to lipid metabolism, such as atherosclerosis, cerebral infarction and chronic heart disease.<sup>29,30</sup> More recent studies have gradually revealed the important role of *APOE* in cell proliferation, tumor angiogenesis, invasion and migration. Dysregulation of *APOE* has been found in a number of cancers, including glioblastoma, gastric cancer, and thyroid cancer.<sup>31–33</sup> Rs429358 and rs7412 are common SNPs in *APOE* and lead to changes in the Cys130Arg and Arg176Cys amino acids, respectively.<sup>34</sup> In this study, we found that rs429358 was a risk variant for thyroid cancer, and rs7412 was a protective variant against the risk of disease, suggesting that rs429358 and rs7412 may participate in the pathogenesis of thyroid cancer by altering the function of *APOE* in cellular lipid catabolism and ferroptosis.

*BCL3* was first identified in chronic lymphocytic leukemia, and subsequent studies found its function as a transcriptional coactivator in the NF- $\kappa$ B signaling pathway.<sup>35</sup> Unlike the general I $\kappa$ B proteins that directly bind to NF- $\kappa$ B proteins and regulate their activity, *BCL3* usually binds to p50 and p52 homodimers to upregulate or suppress a number of genes in the NF- $\kappa$ B pathway.<sup>36</sup> *BCL3* was also identified as a candidate proto-oncogene and plays essential roles in the pathogenesis of tumors.<sup>37</sup> Park et al reported that hepatitis Bx protein can upregulate the expression of *BCL3* and lead to upregulation of the kappaB2 (p52)/*BCL3* complex, thereby participating in the progression of hepatocellular carcinoma.<sup>38</sup> Wakefield et al found that *BCL3* can promote the pulmonary metastasis of ErbB2-positive breast cancer by suppressing cell migration, GDP dissociation and metalloprotease inhibitors.<sup>17</sup> In addition, Chen et al showed that *BCL3* can bind to and inhibit the ubiquitination and degradation of Smad3 and therefore promote the metastasis of breast cancer by regulating TGF $\beta$  signaling.<sup>39</sup> We identified that *BCL3*-s34698726 and rs8100239 were associated with an elevated risk of thyroid cancer under all three genetic models, suggesting that *BCL3* mutations may also contribute to the progression of thyroid cancer. However, the underlying molecular mechanism needs to be explored in further studies.

*ALOX5AP* can stimulate the enzymatic activity of 5-lipoxygenase and convert arachidonic acid into leukotrienes. Leukotrienes are then hydrolyzed into several products in the 5-lipoxygenase pathway and function as inflammatory mediators in the pathogenesis of allergic diseases and chronic inflammatory conditions.<sup>40</sup> *ALOX5AP* was also identified to have essential roles in the occurrence of cancer because of its participation in the 5-lipoxygenase pathway. Jiang et al reported the abnormal expression of *ALOX5AP* in breast cancer and identified it as closely associated with the prognosis of breast cancer patients, suggesting its potential use as a therapeutic target.<sup>41</sup> Recently, Ye et al reported that *ALOX5AP* is upregulated in serous ovarian cancer, and its overexpression is correlated with poor prognosis and survival.<sup>42</sup> Polymorphisms of *ALOX5AP* are also associated with a number of other diseases and cancers, including ischemic stroke, cerebral infarction, lung disease, and breast cancer.<sup>20,43,44</sup> We genotyped two SNPs in *ALOX5AP* in our case–

**Table 5** Association Between SNPs and Risk of Thyroid Cancer in Genetic Models

SNP	Gene	Model	Genotype	Control	Case	OR (95% CI)	p
rs429358	APOE	Dominant	TT	371 (71.3%)	317 (61%)	1	0.0004*
			TC-CC	149 (28.6%)	203 (39%)	1.60 (1.23–2.07)	
		Recessive	TT-TC	508 (97.7%)	503 (96.7%)	1	0.330
			CC	12 (2.3%)	17 (3.3%)	1.45 (0.68–3.06)	
		Log-additive	-	-	-	1.49 (1.18–1.88)	0.0006*
rs7412	APOE	Dominant	CC	376 (72.3%)	427 (82.1%)	1	0.0001*
			CT-TT	144 (27.7%)	93 (17.9%)	0.56 (0.42–0.76)	
		Recessive	CC-CT	510 (98.1%)	517 (99.4%)	1	0.051
			TT	10 (1.9%)	3 (0.6%)	0.29 (0.08–1.06)	
		Log-additive	-	-	-	0.57 (0.43–0.75)	0.0001*
rs34698726	BCL3	Dominant	AA	208 (40%)	166 (31.9%)	1	0.0066*
			TA-TT	312 (60%)	354 (68.1%)	1.42 (1.10–1.84)	
		Recessive	AA-TA	456 (87.7%)	430 (82.7%)	1	0.018*
			TT	64 (12.3%)	90 (17.3%)	1.52 (1.07–2.15)	
		Log-additive	-	-	-	1.34 (1.11–1.60)	0.0016*
rs8100239	BCL3	Dominant	TT	297 (57.1%)	251 (48.3%)	1	0.0037*
			AT-AA	223 (42.9%)	269 (51.7%)	1.44 (1.12–1.84)	
		Recessive	TT-AT	486 (93.5%)	460 (88.5%)	1	0.0049*
			AA	34 (6.5%)	60 (11.5%)	1.86 (1.20–2.89)	
		Log-additive	-	-	-	1.39 (1.15–1.68)	0.0006*
rs4076128	ALOX5AP	Dominant	AA	171 (32.9%)	236 (45.4%)	1	<0.0001*
			GA-GG	349 (67.1%)	284 (54.6%)	0.59 (0.46–0.76)	
		Recessive	AA-GA	438 (84.2%)	460 (88.5%)	1	0.043*
			GG	82 (15.8%)	60 (11.5%)	0.69 (0.48–0.99)	
		Log-additive	-	-	-	0.69 (0.58–0.83)	0.0001*
rs4073259	ALOX5AP	Dominant	AA	175 (33.6%)	158 (30.4%)	1	0.23
			GA-GG	345 (66.3%)	362 (69.6%)	1.17 (0.90–1.52)	
		Recessive	AA-GA	415 (79.8%)	413 (79.4%)	1	0.89
			GG	105 (20.2%)	107 (20.6%)	1.02 (0.76–1.38)	
		Log-additive	-	-	-	1.08 (0.91–1.28)	0.39

**Note:** \*p < 0.05 indicates statistical significance.

**Abbreviations:** SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

**Table 6** Association Between Candidate SNPs and Risk of Thyroid Cancer Stratified by Sex

SNP	Gene	Model	Genotype	Male		Female	
				OR (95% CI)	p	OR (95% CI)	p
rs429358	APOE	Dominant	TT	1.00	0.920	1.00	<0.0001*
			TC-CC	0.98 (0.61–1.56)		2.00 (1.46–2.75)	
		Recessive	TT-TC	1.00	0.950	1.00	0.240
			CC	1.05 (0.26–4.28)		1.69 (0.69–4.16)	
Log-additive	-	0.99 (0.65–1.49)	0.950	1.81 (1.37–2.41)	<0.0001*		
rs7412	APOE	Dominant	CC	1.00	0.010*	1.00	0.004*
			CT-TT	0.49 (0.28–0.85)		0.60 (0.42–0.85)	
		Recessive	CC-CT	1.00	0.110	1.00	0.210
			TT	0.22 (0.02–1.89)		0.37 (0.07–1.91)	
Log-additive	-	0.50 (0.30–0.83)	0.006*	0.61 (0.43–0.85)	0.003*		
rs34698726	BCL3	Dominant	AA	1.00	0.050	1.00	0.035*
			TA-TT	1.57 (1.00–2.47)		1.40 (1.02–1.90)	
		Recessive	AA-TA	1.00	0.046*	1.00	0.170
			TT	1.84 (1.00–3.38)		1.34 (0.88–2.06)	
Log-additive	-	1.47 (1.07–2.02)	0.016*	1.28 (1.03–1.60)	0.028*		
rs8100239	BCL3	Dominant	TT	1.00	0.260	1.00	0.008*
			AT-AA	1.28 (0.83–1.98)		1.49 (1.11–2.01)	
		Recessive	TT-AT	1.00	0.360	1.00	0.004*
			AA	1.40 (0.68–2.86)		2.24 (1.27–3.94)	
Log-additive	-	1.23 (0.89–1.69)	0.210	1.48 (1.17–1.87)	0.001*		
rs4076128	ALOX5AP	Dominant	AA	1.00	0.034*	1.00	0.0008*
			GA-GG	0.62 (0.40–0.97)		0.59 (0.43–0.80)	
		Recessive	AA-GA	1.00	0.006*	1.00	0.530
			GG	0.38 (0.18–0.78)		0.87 (0.57–1.33)	
Log-additive	-	0.61 (0.44–0.86)	0.004*	0.74 (0.60–0.92)	0.007*		
rs4073259	ALOX5AP	Dominant	AA	1.00	0.006	1.00	0.700
			GA-GG	1.96 (1.20–3.18)		0.94 (0.69–1.29)	
		Recessive	AA-GA	1.00	0.800	1.00	0.980
			GG	1.07 (0.64–1.79)		0.99 (0.68–1.45)	
Log-additive	-	1.34 (0.99–1.82)	0.059	0.97 (0.79–1.19)	0.780		

**Note:** \*p < 0.05 indicates statistical significance.

**Abbreviations:** SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.



control cohort and found that *ALOX5AP*-rs4076128 was also correlated with a reduced risk of thyroid cancer. The results provide new clues for functional studies on *ALOX5AP* in thyroid cancer.

Considering the high incidence rate of thyroid cancer in females, we performed a stratification analysis. The results showed that *APOE*-rs7412, *BCL3*-s34698726 and *ALOX5AP*-rs4076128 remained significant in both males and females, while *APOE*-rs429358 and *BCL3*-rs8100239 were associated with the risk of disease only in females. We suppose that *APOE*-rs429358 and *BCL3*-rs8100239 may interact with hormonal regulation in female patients with thyroid cancer, and the relatively small sample size of males may have influenced the different results.

Several limitations of this study need to be highlighted. Although we performed a stratification analysis based on sex, the interaction between candidate SNPs and other factors, such as tumor size and presence or absence of metastasis, could not be evaluated due to the limited information. However, the results identified here could not represent the comprehensive genetic background and driver role of the *APOE*, *BCL3* and *ALOX5AP* genes in patients with thyroid cancer because only seven candidate SNPs were genotyped in this Chinese population. The underlying molecular mechanism between *APOE*, *BCL3* and *ALOX5AP* and thyroid cancer needs to be explored in further functional studies.

In conclusion, the present study found that *APOE*-rs429358, *BCL3*-s34698726 and rs8100239 were associated with an elevated risk of thyroid cancer, while *APOE*-rs7412 and *ALOX5AP*-rs4076128 were related to a reduced risk of disease. The results help us better understand how genetic polymorphisms in ferroptosis-related genes are relevant to thyroid cancer susceptibility.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
2. Deng Y, Li H, Wang M, et al. Global burden of thyroid cancer from 1990 to 2017. *JAMA Netw Open*. 2020;3(6):e208759. doi:10.1001/jamanetworkopen.2020.8759
3. Chmielik E, Rusinek D, Oczko-Wojciechowska M, et al. Heterogeneity of thyroid cancer. *Pathobiology*. 2018;85(1–2):117–129.
4. Laha D, Nilubol N, Boufraqueh M. New therapies for advanced thyroid cancer. *Front Endocrinol*. 2020;11:82. doi:10.3389/fendo.2020.00082
5. Kitahara CM, Preston DL, Neta G, et al. Occupational radiation exposure and thyroid cancer incidence in a cohort of U.S. radiologic technologists, 1983–2013. *Int J Cancer*. 2018;143(9):2145–2149. doi:10.1002/ijc.31270
6. Myung SK, Lee CW, Lee J, Kim J, Kim HS. Risk factors for thyroid cancer: a hospital-based case-control study in Korean adults. *Cancer Res Treat*. 2017;49(1):70–78. doi:10.4143/crt.2015.310
7. Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. *Front Endocrinol*. 2020;11:102. doi:10.3389/fendo.2020.00102
8. Liu R, Xing M. TERT promoter mutations in thyroid cancer. *Endocr Relat Cancer*. 2016;23(3):R143–155. doi:10.1530/ERC-15-0533
9. Khan MS, Qadri Q, Makhdoomi MJ, et al. RET/PTC gene rearrangements in thyroid carcinogenesis: assessment and clinico-pathological correlations. *Pathol Oncol Res*. 2020;26(1):507–513. doi:10.1007/s12253-018-0540-3
10. Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. *J Hematol Oncol*. 2019;12(1):34. doi:10.1186/s13045-019-0720-y
11. Wang Y, Wei Z, Pan K, Li J, Chen Q. The function and mechanism of ferroptosis in cancer. *Apoptosis*. 2020;25(11–12):786–798. doi:10.1007/s10495-020-01638-w
12. Lin R, Fogarty CE, Ma B, et al. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis. *BMC Genomics*. 2021;22(1):576. doi:10.1186/s12864-021-07895-6
13. Ostendorf BN, Bilanovic J, Adaku N, et al. Common germline variants of the human APOE gene modulate melanoma progression and survival. *Nat Med*. 2020;26(7):1048–1053. doi:10.1038/s41591-020-0879-3
14. Chang NW, Chen DR, Wu CT, et al. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. *Breast Cancer Res Treat*. 2005;90(3):257–261. doi:10.1007/s10549-004-4656-7
15. Zhao Z, Zou S, Guan X, et al. Apolipoprotein E overexpression is associated with tumor progression and poor survival in colorectal cancer. *Front Genet*. 2018;9:650. doi:10.3389/fgene.2018.00650
16. Schuster M, Annemann M, Plaza-Sirvent C, Schmitz I. Atypical IκB proteins - nuclear modulators of NF-κB signaling. *Cell Commun Signal*. 2013;11(1):23. doi:10.1186/1478-811X-11-23
17. Wakefield A, Soukupova J, Montagne A, et al. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. *Cancer Res*. 2013;73(2):745–755. doi:10.1158/0008-5472.CAN-12-1321
18. Ahlqvist K, Saamarthy K, Syed Khaja AS, Bjartell A, Massoumi R. Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer. *Oncogene*. 2013;32(12):1601–1608. doi:10.1038/onc.2012.175
19. Puvvada SD, Funkhouser WK, Greene K, et al. NF-κB and Bcl-3 activation are prognostic in metastatic colorectal cancer. *Oncology*. 2010;78(3–4):181–188. doi:10.1159/000313697



20. Wang J, John EM, Ingles SA. 5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2008;17(10):2748–2754. doi:10.1158/1055-9965.EPI-08-0439
21. Saadat M. Apolipoprotein E (APOE) polymorphisms and susceptibility to breast cancer: a meta-analysis. *Cancer Res Treat*. 2012;44(2):121–126. doi:10.4143/crt.2012.44.2.121
22. Kato I, Land S, Barnholtz-Sloan J, Severson RK. APOE and FABP2 polymorphisms and history of myocardial infarction, stroke, diabetes, and gallbladder disease. *Cholesterol*. 2011;2011:896360. doi:10.1155/2011/896360
23. Galal AA, Abd Elmajeed AA, Elbaz RA, Wafa AM, Elshazli RM. Association of Apolipoprotein E gene polymorphism with the risk of T2DM and obesity among Egyptian subjects. *Gene*. 2021;769:145223. doi:10.1016/j.gene.2020.145223
24. Hong CC, Sucheston-Campbell LE, Liu S, et al. Genetic variants in immune-related pathways and breast cancer risk in african american women in the AMBER consortium. *Cancer Epidemiol Biomarkers Prev*. 2018;27(3):321–330. doi:10.1158/1055-9965.EPI-17-0434
25. Dimitrakopoulos FI, Antonacopoulou AG, Kottorou A, et al. Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients. *Lung Cancer*. 2015;89(3):311–319. doi:10.1016/j.lungcan.2015.06.006
26. Zhang R, Guo X, Li X, et al. Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene rs4073259 polymorphism not associated with ischemic stroke in the northeastern Chinese Han population. *Clin Neurol Neurosurg*. 2014;119:64–69. doi:10.1016/j.clineuro.2014.01.004
27. Zhang SY, Xu ML, Zhang CE, et al. Association of ALOX5AP gene single nucleotide polymorphisms and cerebral infarction in the Han population of northern China. *BMC Med Genet*. 2012;13:61. doi:10.1186/1471-2350-13-61
28. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. *Biol Chem*. 1998;379(8–9):951–964.
29. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and alzheimer's disease in the Rotterdam study. *Lancet*. 1997;349(9046):151–154. doi:10.1016/S0140-6736(96)09328-2
30. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. *Arterioscler Thromb Vasc Biol*. 1996;16(10):1250–1255. doi:10.1161/01.ATV.16.10.1250
31. Nicoll JA, Zunarelli E, Rampling R, Murray LS, Papanastassiou V, Stewart J. Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome. *Neuroreport*. 2003;14(15):1923–1926.
32. Oue N, Hamai Y, Mitani Y, et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. *Cancer Res*. 2004;64(7):2397–2405. doi:10.1158/0008-5472.CAN-03-3514
33. Ito Y, Takano T, Miyauchi A. Apolipoprotein e expression in anaplastic thyroid carcinoma. *Oncology*. 2006;71(5–6):388–393. doi:10.1159/000107112
34. Seripa D, D'Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A. The genetics of the human APOE polymorphism. *Rejuvenation Res*. 2011;14(5):491–500. doi:10.1089/rej.2011.1169
35. Hatada EN, Nieters A, Wulczyn FG, et al. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. *Proc Natl Acad Sci U S A*. 1992;89(6):2489–2493. doi:10.1073/pnas.89.6.2489
36. Legge DN, Chambers AC, Parker CT, Timms P, Collard TJ, Williams AC. The role of B-Cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis. *Carcinogenesis*. 2020;41(3):249–256. doi:10.1093/carcin/bgaa003
37. Maldonado V, Melendez-Zajgla J. Role of Bcl-3 in solid tumors. *Mol Cancer*. 2011;10:152. doi:10.1186/1476-4598-10-152
38. Park SG, Chung C, Kang H, Kim JY, Jung G. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. *J Biol Chem*. 2006;281(42):31770–31777. doi:10.1016/S0021-9258(19)84092-9
39. Chen X, Cao X, Sun X, et al. Bcl-3 regulates TGFβ signaling by stabilizing Smad3 during breast cancer pulmonary metastasis. *Cell Death Dis*. 2016;7(12):e2508. doi:10.1038/cddis.2016.405
40. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. *Prostaglandins Other Lipid Mediat*. 2007;83(3):188–197. doi:10.1016/j.prostaglandins.2007.01.005
41. Jiang WG, Douglas-Jones AG, Mansel RE. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. *Prostaglandins Leukot Essent Fatty Acids*. 2006;74(2):125–134. doi:10.1016/j.plefa.2005.10.005
42. Ye X, An L, Wang X, et al. ALOX5AP predicts poor prognosis by enhancing M2 macrophages polarization and immunosuppression in serous ovarian cancer microenvironment. *Front Oncol*. 2021;11:675104. doi:10.3389/fonc.2021.675104
43. Shi Y, Xu L, Feng Q, et al. Allele-specific methylation contributed by CpG-SNP is associated with regulation of ALOX5AP gene expression in ischemic stroke. *Neurol Sci*. 2018;39(10):1717–1724. doi:10.1007/s10072-018-3489-9
44. Kowal-Bielecka O, Chwiesko-Minarowska S, Bernatowicz PL, et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European scleroderma trials and research group (EUSTAR) study. *Rheumatology*. 2017;56(5):844–852. doi:10.1093/rheumatology/kew499

## Pharmacogenomics and Personalized Medicine

Dovepress

### Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>